Larkberget (LARK.ST) Stock Price

Larkberget Price

OMX·CLOSED
2.21
​
Market closed

Revenue at Larkberget has contracted by 27.2% per year over the past 7 years to 325,600.00 SEK. Larkberget's net margin stands at -13,783.1%, up from -162,297.5% several years earlier.

Larkberget stock price

Access this data via the Eulerpool API

Larkberget business model & stock analysis

CombiGene AB engages in the development of new treatment for neurological diseases. The company is headquartered in Lidingoe, Stockholm. The company went IPO on 2015-05-25. The firm specializes in development of treatments for neurological disorders. The firm's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The firm focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Frequently asked questions about Larkberget

Converted at the current exchange rate, the Larkberget share trades at 0.20 EUR (2.21 SEK).

The Larkberget share (LARK.ST) is listed on 3 stock exchanges, including: Frankfurt (COJ0.F), Stockholm (COMBI.ST).

The revenue cannot currently be calculated for Larkberget.

The profit cannot currently be calculated for Larkberget.

The P/E ratio cannot be calculated for Larkberget at the moment.

The P/S cannot be calculated for Larkberget currently.

The Eulerpool Quality Score for Larkberget is 1/10.

The ISIN of Larkberget is SE0016101935. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Larkberget is A3CRDS. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Larkberget is LARK.ST. The ticker symbol is used to trade Larkberget shares on the stock exchange.

Fair ValueTerminal
1.99 SEK
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Sweden
Currency
SEK
Initial public offering
May 25, 2015
ISIN
SE0016101935
Cusip
W2R056269
Market capitalization
43.76 M SEKMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
0.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-62.33 %
Gross Margin
—
EBIT Margin
-14,501.72 %
Net Margin
-13,783.11 %
EPS (Earnings Per Share)
-2.27 SEK
Net Debt / EBIT
0.00
Debt/Equity
0.00
Last updated Oct 1, 2026, 2:03 AM

Larkberget Peer Group

Larkberget Ticker

FRANKFURT · COJ0.FSTOCKHOLM · COMBI.STSTOCKHOLM · COMBI.ST

Larkberget FIGI

COMBI:SF · BBG008GSRXC8COMBISEK:XH · BBG00JZBCDY6COMBISEK:XF · BBG00JZBCF08COMBISEK:XE · BBG00JZBCF26COMBISEK:XL · BBG00JZBCF44COMBISEK:XG · BBG00JZBCF53COMBISEK:XO · BBG00JZBCF62COMBISEK:XA · BBG00JZBCFC5COMBISEK:XT · BBG00JZBCFF2COMBISEK:XW · BBG00JZBCFG1COMBISEK:XU · BBG00JZBCFH0COMBISEK:XV · BBG00JZBCFJ8

All fundamentals and in-depth analysis of Larkberget

Our stock analysis for Larkberget stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Larkberget. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.